Rituximab therapy in pericarditis associated with rheumatoid arthritis
- 05.01.2022
- Case Based Review
Erschienen in:
- Verfasst von
- Ali Taylan
- Erschienen in
- Rheumatology International | Ausgabe 10/2022
Abstract
In rheumatoid arthritis, pericarditis is commonly asymptomatic, but rarely, it progresses to a morbid complication, like cardiac tamponade or restrictive pericarditis. Current studies have indicated that conventional drugs have limited ability to reverse these lethal conditions. To date, invasive surgical measures remain the only definitive therapy for patients who are unresponsive to drugs. Recently, anti-tumor necrosis factor-α and anti-interleukin-1 antibody-based drugs have shown limited success. Consequently, given the importance of pericarditis, we need new treatment methods. Here, we describe a patient with rheumatoid arthritis and effusive pericarditis, which progressed to life-threatening cardiac tamponade. The patient responded very well to rituximab. Thus, rituximab represents a potential new therapy for this rarely treated complication of rheumatoid arthritis.
Anzeige
- Titel
- Rituximab therapy in pericarditis associated with rheumatoid arthritis
- Verfasst von
-
Ali Taylan
- Publikationsdatum
- 05.01.2022
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Rheumatology International / Ausgabe 10/2022
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X - DOI
- https://doi.org/10.1007/s00296-021-05080-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
